Literature DB >> 28273424

Is Quadriceps Tendon Autograft a Better Choice Than Hamstring Autograft for Anterior Cruciate Ligament Reconstruction? A Comparative Study With a Mean Follow-up of 3.6 Years.

Etienne Cavaignac1,2, Benoit Coulin1,2, Philippe Tscholl1,2, Nik Nik Mohd Fatmy1,2, Victoria Duthon1,2, Jacques Menetrey1,2.   

Abstract

BACKGROUND: The quadriceps tendon (QT) autograft is known as an effective graft for anterior cruciate ligament (ACL) reconstruction and shows a similar functional outcome to the bone-patellar tendon-bone (BPTB) in randomized controlled trials, with a lesser incidence of complications. Up until now, only 2 studies have compared QT to hamstring tendon (HT) autograft. HYPOTHESIS: The functional outcomes of the QT technique are at least as good as those of the HT technique, with the same morbidity. STUDY
DESIGN: Cohort study; Level of evidence, 3.
METHODS: Ninety-five patients underwent isolated ACL reconstruction between January 1 and December 31, 2012. Fifty underwent ACL reconstruction with the QT and 45 with the HT. The same surgical technique, fixation method, and postoperative protocol were used in both groups. The following parameters were evaluated: surgical revisions, functional outcome (Lysholm, Knee injury and Osteoarthritis Outcome Score [KOOS], Tegner, subjective International Knee Documentation Committee), joint stability (KT-1000, Lachman, pivot shift), anterior knee pain (Shelbourne-Trumper score), and isokinetic strength. Descriptive statistics are presented for these variables using the Student t test.
RESULTS: Eighty-six patients (45 QT, 41 HT) were reviewed with a mean follow-up of 3.6 ± 0.4 years; minimum follow-up was 3 years. There were 4 reoperations in the QT group (including 1 ACL revision) and 3 in the HT group (including 2 ACL revisions) ( P > .05). The Lysholm (89 ± 6.9 vs 83.1 ± 5.3), KOOS Symptoms (90 ± 11.2 vs 81 ± 10.3), and KOOS Sport (82 ± 11.3 vs 67 ± 12.4) scores were significantly better in the QT group than in the HT group. In terms of stability, the mean side-to-side difference was 1.1 ± 0.9 mm for the QT group and 3.1 ± 1.3 mm for the HT group based on KT-1000 measurements ( P < .005). The negative Lachman component was higher in the QT group than in the HT group (90% vs 46%, P < .005). There was a trend for the negative pivot-shift component to be higher in the QT group than in the HT group (90% vs 64%, P = .052). The Shelbourne-Trumper score was the same in both groups. There was no difference between groups in terms of isokinetic strength.
CONCLUSION: The use of a QT graft in ACL reconstruction leads to equal or better functional outcomes than does the use of an HT graft, without affecting morbidity.

Entities:  

Keywords:  anterior cruciate ligament; quadriceps tendon; sports medicine

Mesh:

Year:  2017        PMID: 28273424     DOI: 10.1177/0363546516688665

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  38 in total

1.  ACL Study Group survey reveals the evolution of anterior cruciate ligament reconstruction graft choice over the past three decades.

Authors:  Markus P Arnold; Jacob G Calcei; Nicole Vogel; Robert A Magnussen; Mark Clatworthy; Tim Spalding; John D Campbell; John A Bergfeld; Seth L Sherman
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-01-24       Impact factor: 4.342

2.  Predicting adequacy of free quadriceps tendon autograft, for primary and revision ACL reconstruction, from patients' physical parameters.

Authors:  Anthony Ugwuoke; Farhan Syed; Sam El-Kawy
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-07-30       Impact factor: 4.342

3.  The role of muscle function after anterior cruciate ligament rupture and treatment.

Authors:  Roland Becker; Jon Karlsson
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2018-02       Impact factor: 4.342

4.  Implications for Early Postoperative Care After Quadriceps Tendon Autograft for Anterior Cruciate Ligament Reconstruction: A Technical Note.

Authors:  Jennifer L Hunnicutt; Harris S Slone; John W Xerogeanes
Journal:  J Athl Train       Date:  2020-06-23       Impact factor: 2.860

5.  Aperture and Suspensory Fixation Equally Efficacious for Quadriceps Tendon Graft Fixation in Primary ACL Reconstruction: A Systematic Review.

Authors:  Raphael J Crum; Darren de Sa; Ajay C Kanakamedala; Obianuju A Obioha; Bryson P Lesniak; Volker Musahl
Journal:  J Knee Surg       Date:  2019-04-08       Impact factor: 2.757

Review 6.  Current trends in the anterior cruciate ligament part II: evaluation, surgical technique, prevention, and rehabilitation.

Authors:  Volker Musahl; Ian D Engler; Ehab M Nazzal; Jonathan F Dalton; Gian Andrea Lucidi; Jonathan D Hughes; Stefano Zaffagnini; Francesco Della Villa; James J Irrgang; Freddie H Fu; Jon Karlsson
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-12-05       Impact factor: 4.342

7.  Comparison of knee extensor strength after anterior cruciate ligament reconstruction using either quadriceps tendon or hamstring tendon autografts.

Authors:  C Horteur; B Rubens Duval; A Merlin; J Cognault; M Ollivier; R Pailhe
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-06-21

8.  Comparison of hamstring and quadriceps tendon autografts in anterior cruciate ligament reconstruction with gait analysis and surface electromyography.

Authors:  J Schagemann; T Koebrich; R Wendlandt; A P Schulz; J Gille; R Oheim
Journal:  J Orthop Traumatol       Date:  2021-05-21

9.  The outcomes of quadriceps tendon autograft for anterior cruciate ligament reconstruction in adolescent athletes: a retrospective case series.

Authors:  Natalie H Vaughn; Mark L Dunleavy; Trevor Jackson; William Hennrikus
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-06-10

10.  Bone Versus All Soft Tissue Quadriceps Tendon Autografts for Anterior Cruciate Ligament Reconstruction: A Systematic Review.

Authors:  Raphael J Crum; Jeffrey Kay; Bryson P Lesniak; Alan Getgood; Volker Musahl; Darren de Sa
Journal:  Arthroscopy       Date:  2020-10-21       Impact factor: 4.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.